@GiacomoScudiero @BernieSanders Health Econ Review: Among pharma companies, “a higher presence in Europe is associated with lower R&D investments. The results can be interpreted as further evidence of the deteriorating effect of regulation on firm’s
@karnex47 @emptyroomyeller @BernieSanders Interesting that the UK & Switzerland claim a higher proportion of NMEs. But it seems to not be conclusive on the R&D issue: “..further evidence of deteriorating effect of regulation on...incentives to inve
@P_lynch17 @GenericUserX2 @scottsantens @donttrythis "An increase of R&D investment makes economically only sense if it leads to more drugs that meet an unmet medical need and make a significant difference to the patient." From https://t.co/fCgkyF5Ned